tiprankstipranks
Advertisement
Advertisement

FHTX Stock Latest News

Foghorn Therapeutics Stockholders Approve Directors and Governance Matters
Company AnnouncementsFoghorn Therapeutics Stockholders Approve Directors and Governance Matters
15d ago
8K
FHTX
Foghorn Therapeutics reports Q1 EPS (29c), consensus (31c)
PremiumThe Fly
Foghorn Therapeutics reports Q1 EPS (29c), consensus (31c)
2M ago
FHTX
Foghorn Therapeutics Highlights Q1 Progress in Oncology Pipeline
PremiumCompany Announcements
Foghorn Therapeutics Highlights Q1 Progress in Oncology Pipeline
2M ago
8K
FHTX
Foghorn Therapeutics: AACR 2026 Data De‑Risk Pipeline and Expand Commercial Opportunity, Supporting Buy Rating and $13 Target
PremiumRatings
Foghorn Therapeutics: AACR 2026 Data De‑Risk Pipeline and Expand Commercial Opportunity, Supporting Buy Rating and $13 Target
3M ago
FHTX
Foghorn Therapeutics presents new preclinical data for FHD-909
PremiumThe Fly
Foghorn Therapeutics presents new preclinical data for FHD-909
3M ago
FHTX
Foghorn Highlights Preclinical Chromatin Oncology Advances at AACR
PremiumCompany AnnouncementsFoghorn Highlights Preclinical Chromatin Oncology Advances at AACR
3M ago
8K
FHTX
Maintaining Buy on Foghorn: Advancing FHD-909, Productive Discovery Engine, and Cash Runway Drive Attractive Risk–Reward Ahead of Key 2026 Catalyst
Premium
Ratings
Maintaining Buy on Foghorn: Advancing FHD-909, Productive Discovery Engine, and Cash Runway Drive Attractive Risk–Reward Ahead of Key 2026 Catalyst
4M ago
FHTX
Buy Rating on Foghorn Therapeutics Driven by Lilly Partnership Catalyst, Advancing Degrader Pipeline, and Strengthened Cash Runway
Premium
Ratings
Buy Rating on Foghorn Therapeutics Driven by Lilly Partnership Catalyst, Advancing Degrader Pipeline, and Strengthened Cash Runway
4M ago
FHTX
Foghorn Advances FHD-909 Trial and Strengthens Financial Position
PremiumCompany Announcements
Foghorn Advances FHD-909 Trial and Strengthens Financial Position
4M ago
8K
FHTX
Reigniting FHD-286: Chromatin-Targeted Synergy in Menin-Resistant AML Underpins Buy Rating on Foghorn
PremiumRatings
Reigniting FHD-286: Chromatin-Targeted Synergy in Menin-Resistant AML Underpins Buy Rating on Foghorn
4M ago
FHTX
Is FHTX a Buy, Before Earnings?
PremiumPre-Earnings
Is FHTX a Buy, Before Earnings?
4M ago
FHTX
Foghorn Therapeutics Names Veteran Executive as New CFO
PremiumCompany Announcements
Foghorn Therapeutics Names Veteran Executive as New CFO
5M ago
8K
FHTX
Foghorn Therapeutics appoints Maynard as Chief Financial Officer
PremiumThe FlyFoghorn Therapeutics appoints Maynard as Chief Financial Officer
5M ago
FHTX
Foghorn Therapeutics price target lowered to $12 from $14 at Jefferies
Premium
The Fly
Foghorn Therapeutics price target lowered to $12 from $14 at Jefferies
5M ago
FHTX
Jefferies Initiates Buy on Foghorn Therapeutics Driven by FHD‑909 Mid‑2026 Catalyst and Upside from Emerging EP300/CBP Degrader Pipeline
Premium
Ratings
Jefferies Initiates Buy on Foghorn Therapeutics Driven by FHD‑909 Mid‑2026 Catalyst and Upside from Emerging EP300/CBP Degrader Pipeline
5M ago
FHTX
Foghorn Therapeutics Announces $50 Million Equity Financing
PremiumCompany Announcements
Foghorn Therapeutics Announces $50 Million Equity Financing
6M ago
8K
FHTX
3 ‘Strong Buy’ Stocks to Buy Today, 12/18/2025, According to Top Analysts
PremiumMarket News
3 ‘Strong Buy’ Stocks to Buy Today, 12/18/2025, According to Top Analysts
7M ago
FHTX
NUVL
Foghorn Therapeutics initiated with a Buy at BTIG
PremiumThe Fly
Foghorn Therapeutics initiated with a Buy at BTIG
7M ago
FHTX
Foghorn Therapeutics Appoints Interim CFO Jeff Sacher
PremiumCompany Announcements
Foghorn Therapeutics Appoints Interim CFO Jeff Sacher
7M ago
8K
FHTX
Promising Developments and Strategic Partnerships Position Foghorn Therapeutics for Growth: A Buy Rating by Laura Prendergast
PremiumRatingsPromising Developments and Strategic Partnerships Position Foghorn Therapeutics for Growth: A Buy Rating by Laura Prendergast
7M ago
FHTX
Foghorn Therapeutics initiated with a Buy at Stifel
Premium
The Fly
Foghorn Therapeutics initiated with a Buy at Stifel
7M ago
LLY
FHTX
Strategic Drug Development and Scientific Rigor Drive Buy Rating for Foghorn Therapeutics
Premium
Ratings
Strategic Drug Development and Scientific Rigor Drive Buy Rating for Foghorn Therapeutics
8M ago
FHTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >